ClinicalTrials.gg
RecruitingNCT07134998Updated Dec 5, 2025

Phase I Study of HRS-6093 in Participants With Advanced Solid Tumors Harboring KRAS G12D Mutations

A Phase 1 interventional study of HRS-6093 in Advanced KRAS G12D Mutant Solid Tumors, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-05.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
153
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, multi-center phase I clinical study to evaluate HRS-6093 Safety, Tolerability, and Pharmacokinetics in Participants harboring KRAS G12D Mutations with advanced solid tumors. The study consists of dose escalation, dose expansion and efficacy expansion.

02

Conditions studied

  • Advanced KRAS G12D Mutant Solid Tumors
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;
  2. Aged between 18-75 years, with no gender requirement;
  3. Participants with histologically/ confirmed advanced solid tumors who have been previously tested or are confirmed by the central laboratory to harbor KRAS G12D mutations; Have failed standard treatment, are intolerant to standard treatment, or have not received standard treatment.
  4. performance status (PS) score of 0 or 1;
  5. > 3 months;
  6. At least one per v1.1; A tumor tissue sample must be provided.
  7. Adequate organ function

Exclusion criteria

Exclusion Criteria:

  1. Toxicity (e.g., gastrointestinal reaction and skin toxicity) from prior anti-tumor treatment has not recovered to Grade ≤ 1 or a level specified in the inclusion/exclusion criteria;
  2. Presence of central nervous system (CNS) ;
  3. Participants with gastrointestinal diseases that affect drug administration/absorption
  4. Participants who have undergone major surgery other than diagnosis or within 28 days before the first dose, or are expected to undergo major surgery during the study period;
  5. Presence of serious pulmonary diseases
  6. Active tuberculosis or a history of active tuberculosis infection within 48 weeks prior to screening, regardless of whether they have been treated;
  7. Active or persistent gastrointestinal bleeding within 6 months prior to screening;
  8. History of allogeneic bone marrow or solid organ transplantation;
  9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;
  10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;
  11. Positive (HIV) (HIV1/2 antibodies), active chronic , or active (positive HCV antibody and positive HCV RNA);
  12. Known history of to any component of the drug product to be used in the study;
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
153 participants (estimated)

Study arms

  • Experimental
    HRS-6093

    Drug: HRS-6093

Interventions

  • DrugHRS-6093

    HRS-6093

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events/serious adverse events (graded as per CTCAE v5.0).

    Time frame: Screening Period to 30 Days After the Last Dose

  2. DLT,

    Time frame: from day1 to day 23; 23 Days

  3. MTD,

    Time frame: from day1 to day 23; 23 Days

  4. RP2D ,

    Time frame: 24 months

Secondary outcomes

  1. Number of Participants With Abnormal Laboratory Values

    Time frame: Screening Period to 30 Days After the Last Dose; 24 months

  2. Number of subjects with clinically significant changes in ECOG, vital signs and physical examination.

    Time frame: Screening Period to 30 Days After the Last Dose; 24 months

  3. Number of subjects with changes on ECG.

    Time frame: Screening Period to 30 Days After the Last Dose; 24 months

  4. maximum plasma concentration (Cmax),

    Time frame: Screening Period to Day of the end of treatment/withdrawal. 24 months

  5. time to maximum concentration (Tmax),

    Time frame: Screening Period to Day of the end of treatment/withdrawal. 24 months

  6. area under concentration-time curve from time 0 to the last measurable concentration time point t (AUC0-t),

    Time frame: Screening Period to Day of the end of treatment/withdrawal. 24 months

  7. Area under concentration-time curve from time 0 to infinity (AUC 0-∞), apparent volume of distribution (Vz/F),

    Time frame: Screening Period to Day of the end of treatment/withdrawal. 24 months

  8. elimination half-life (t1/2), and apparent clearance (CL/F);

    Time frame: Screening Period to Day of the end of treatment/withdrawal. 24 months

  9. minimum concentration at steady state (Cmin, ss),

    Time frame: Screening Period to Day of the end of treatment/withdrawal. 24 months

  10. area under the blood concentration-time curve at steady state (AUCss), and accumulation ratio (Rac);

    Time frame: Screening Period to Day of the end of treatment/withdrawal. 24 months

  11. objective response rate (ORR),

    Time frame: Screening Period to PD; 24 months

  12. duration of response (DoR),

    Time frame: Screening Period to PD; 24 months

  13. disease control rate (DCR),

    Time frame: Screening Period to PD; 24 months

  14. progression-free survival (PFS),

    Time frame: Screening Period to PD; 24 months

  15. overall survival (OS).

    Time frame: Screening Period to Day of death of the participant;24months

07

Study locations

2 of 2 sites recruiting
  • Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200025, China
    Recruiting
    • Baiyong Shen · Principal investigator
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
    Recruiting
    • Dan Cao · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for May 2028, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2025
First posted
Aug 21, 2025
StartActual
Sep 16, 2025
Primary completionEst.
May 2028
CompletionEst.
Dec 2028
Last update
Dec 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07134998
Responsible party
Sponsor
First posted
Aug 21, 2025
Start date
Sep 16, 2025
Primary completion
May 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Dec 5, 2025

Study contacts

Rongfu Mao
Contact
rongfu.mao@hengrui.com
+86 021-61053363
Jizhao Li
Contact
jizhao.li.jl565@hengrui.com
+86 021-61053363

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion